Fact CheckerSign in

NCT05153954Completed

Quantitative ICG Fluorescence Angiography in Colorectal Surgery

Quantitative ICG Fluorescence Angiography in Colorectal Surgery (QUANTICO): a Protocol for a Prospective, Standardized, Observational, Surgeon-blinded Multi-center Trial

Source: ClinicalTrials.gov · Last updated 3 Dec 2024

Brief summary (registry, in English)

Fluorescence angiography with indocyanine green (ICG-FA) has gained increased popularity in colorectal surgery to check perfusion to the newly-formed anastomotic area and decrease the rate of postoperative anastomotic leakage. While qualitative ICG assessment has the advantage to be used instantly during the operative procedure, it does bear drawbacks (subjective assessment, dependent on factors like camera distance, ICG dose and white-light contamination). The alternative is quantitative ICG assessment, which is performed by evaluating the time-intensity curve of the ICG-FA with an external analyzing software. The procedure is showing promising results, but the methodology is still reported very heterogeneously. This study is a multi-center, prospective, standardized, surgeon-blinded observational trial. The key aspect of this study is the non-interventional design with blinding of both the qualitative and quantitative results from the ICG perfusion measurement, providing no chance of influencing the course of the operation. Assessment of perfusion will be performed postoperatively blinded to the outcome. Assessment of the pre-anastomotic area is intraoperatively performed by an image analysis software that then calculates a perfusion score based on an algorithm integrating relevant perfusion metrics. The primary outcome is the combined rate of early and late anastomotic complications within 90 days postoperatively.

Status (registry)
Completed
Study type
Observational
Enrollment
114 (actual)
First submitted
24 Sept 2021
Start date
31 Aug 2021
Primary completion date
31 Aug 2024
Lead sponsor
Zealand University Hospital
NCT number
NCT05153954

What you commit to

  • Study type: Observational
  • Participants enrolled: 114
  • From 31 Aug 2021 to the primary completion date, 31 Aug 2024
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Known allergy to ICG or iodine

Other

  • Emergency procedure
  • Pregnancy or if the patient is currently nursing
  • Surgeons decide to do unblinded quantitative or qualitative ICG-FA

Who the study is looking for

  • Age 18 years or older
  • Capable of giving informed consent
  • ASA Classification: status I-III
  • Planned for PME or TME with minimally invasive approach and primary anastomosis
  • Strong suspicion of or biopsy-verified sigmoid or rectal cancer Stage I-IV cancer

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Department of Surgery, Herlev Hospital
Coordinator of this site? Confirm its status
HerlevDenmarkUnknown status
Department of Surgery, Zealand University Hospital
Coordinator of this site? Confirm its status
KøgeDenmarkUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.